Immunovant (IMVT) Change in Cash (2019 - 2026)

Immunovant has reported Change in Cash for 8 years, with the latest figure at -$92.4 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Cash fell 127.24% year-over-year to -$92.4 million; the trailing twelve-month figure through Mar 2026 stood at $188.1 million (up 139.34% YoY), and the FY2026 full-year result was $188.1 million, up 139.34% from the prior year.
• Change in Cash for Q1 2026 stood at -$92.4 million, down from $472.7 million in the prior quarter.
• The five-year high for Change in Cash was $472.7 million in Q4 2025, with the low at -$115.1 million in Q2 2025.
• Historically, Change in Cash has averaged $22.1 million across 5 years, with a median of -$56.1 million in 2023.
• Annual changes were most pronounced in 2022 — Change in Cash plunged 215.08% — and 2023, when it jumped 1468.88%.
• Immunovant's Change in Cash stood at $26.8 million in 2022, then jumped by 1468.88% to $421.0 million in 2023, then slumped by 123.34% to -$98.3 million in 2024, then jumped by 581.04% to $472.7 million in 2025, then sank by 119.55% to -$92.4 million in 2026.
• The last three Change in Cash figures came in at -$92.4 million (Q1 2026), $472.7 million (Q4 2025), and -$77.0 million (Q3 2025), per Business Quant data.